Fidelma L. Fitzpatrick

The Paint Still in the Walls

Fidelma Fitzpatrick learned to build a trial across generations: the advertisement sold in one century, the dust released in another, and the child whose blood carried both.

In February 2006, after more than three months of testimony in Providence, a Rhode Island jury found former lead-pigment manufacturers responsible for creating a public nuisance. The case had begun in 1999, endured a seven-week trial that ended without a verdict, and returned for a second trial.

Fidelma Fitzpatrick had worked on it from the beginning. She carried much of the legal research, examined witnesses, and stood before the jury in opening and closing. The proof stretched across old medical journals, trade-association records, advertisements, chemistry, housing stock, and the daily mechanics of a painted window. To make the case intelligible, she had to collapse a century into a room a child could touch.

Rhode Island supplied a first. California would supply the enduring remedy. Between them, Fitzpatrick developed the form of advocacy that came to define her career: find the product whose usefulness outlived its sale, recover the knowledge buried behind it, and make an old corporate decision answer to the person still living with its consequences.

The Child at the Window

A painted window creates dust through ordinary use. The sash rises. The frame rubs. Pigment loosens and settles on the sill and floor. A young child touches the surface and then puts a hand in her mouth. The distance from wall to bloodstream can be shorter than the room is wide.

Lead gave paint durability, opacity, and color. Manufacturers promoted it for residential interiors while medical knowledge of childhood poisoning deepened. The sale eventually ended. The paint remained on windows, doors, kitchens, nurseries, and baseboards, often sealed beneath later coats until age, friction, or renovation released it again.

Ten California cities and counties sued former manufacturers on behalf of people living with that residue. Their public-nuisance case followed the companies’ promotion of residential lead paint and the danger embedded wherever it had been applied. The requested remedy was practical: inspect homes, educate families, stabilize dangerous surfaces, and remove or contain the paint before another child encountered its dust.

Fitzpatrick served as co-lead trial counsel. Fitzpatrick and the team had to assemble evidence spanning decades while proving knowledge, promotion, and causation under California law. Hundreds of advertisements, trade materials, scientific publications, and internal documents had to meet census data, housing records, public-health evidence, and the mechanics of exposure inside an occupied home.

The Dutch Boy in the Nursery

The marketing had been intimate. National Lead’s Dutch Boy appeared in palettes, booklets, and campaigns addressed to families. Lead paint was presented as cleanliness, beauty, and protection for the rooms where children slept and played. The image made a hazardous industrial ingredient feel domestic.

At trial, Fitzpatrick’s team linked the industry’s early promotion to later exposure. A century-old advertisement remained relevant because the paint it sold still occupied a California window. Medical literature described the same pigment a child could inhale generations later. Trade campaigns remained relevant because lead paint persisted in the housing stock.

The trial court entered a $1.15 billion abatement judgment in 2014. Appellate review refined the years and homes supported by the evidence, focusing the remedy on pre-1951 housing in the participating jurisdictions. In 2019, after nearly two decades of litigation, the companies agreed to a $305 million settlement devoted to inspection, education, and the safe removal or containment of lead paint.

The settlement paid for work inside real houses. Inspectors could test windows and doors, crews could contain dust and replace dangerous surfaces, and families could learn where lead traveled. Fitzpatrick’s courtroom had been filled with century-old documents; the remedy arrived with tools, protective coverings, and clean sills.

The Lawyer Who Stayed

Fitzpatrick had not planned a career around products whose effects persist for decades. After graduating from American University’s Washington College of Law in 1994, she began with gender-discrimination cases. Three years later, she joined the lawyers who would form Motley Rice and entered state litigation against the tobacco industry.

She has described the arrival as luck. Staying was a choice. Plaintiff-side practice allowed her to represent people facing institutions with deeper records, larger budgets, and years of accumulated scientific knowledge. It also matched a trait visible in every major matter she later handled: she is drawn toward the situation another lawyer has already called impossible.

Through tobacco litigation, Fitzpatrick learned to trace corporate knowledge across laboratories, subsidiaries, trade associations, outside counsel, marketing departments, and committees, then connect that history to the exposure and disease of an individual client.

That principle carried Fitzpatrick through Rhode Island’s two lead trials and into California. Public-health cases can spend years in discovery and appeal before a remedy reaches anyone. Fitzpatrick stayed long enough to see the evidence become an abatement fund.

Three Childhoods in Milwaukee

Glenn Burton Jr., Ravon Owens, and Cesar Sifuentes grew up in Milwaukee houses built between 1899 and 1922. As toddlers, each absorbed white lead carbonate from old paint. Their peak blood-lead levels ranged from 31 to 53 micrograms per deciliter. Owens and Sifuentes required hospitalization and chelation therapy. The exposure followed all three into adulthood through learning and reading difficulties that narrowed school, work, and opportunity.

Time had erased the ordinary chain of product identification. No surviving can established which company’s pigment occupied each childhood wall. Wisconsin’s risk-contribution doctrine supplied another route: manufacturers that had helped create and market the dangerous product could answer according to their participation in the relevant market unless they proved they had not contributed.

Fitzpatrick served as co-lead trial counsel in the consolidated federal trial. Common evidence described the pigment, the companies, the warnings, and the history. Individual evidence restored the three lives. Each man had a different home, blood record, education, and adult path. The science created a field of proof; biography showed the damage within it.

During closing argument, Fitzpatrick gave the injury a physical image: “Lead is a weight on their shoulders.” It burdened reading comprehension, career choice, and the ability to use talents that childhood exposure had constrained.

After a three-week trial in 2019, the jury awarded $2 million to each man. The Seventh Circuit later returned the judgments for further proceedings under a narrower reading of Wisconsin products-liability law. The bellwether still accomplished something the decades had made difficult: it placed the three childhoods, the historical market, and the manufacturers’ conduct inside one public trial record.

Fitzpatrick described the work as giving the men a voice in court. The phrase was more than professional sentiment. Their cases arose because the product could no longer be traced in the usual way. The courtroom supplied the place where their medical records, childhood homes, and adult testimony could be heard together.

The Coil Intended to Remain

Essure was marketed as permanent birth control without abdominal surgery. Physicians placed flexible metal coils in the fallopian tubes, where tissue growth was intended to create a lasting barrier. Thousands of women later reported migration, perforation, chronic pain, bleeding, and other injuries. Removal could require hysterectomy or major reconstructive surgery.

Fitzpatrick led the plaintiffs’ executive committee in coordinated California litigation that grew from fewer than one thousand cases to more than thirty thousand. Common discovery addressed design, testing, regulatory history, warnings, and the manufacturer’s knowledge. Individual files traced insertion, symptoms, imaging, lost fertility, and the operations required after the device ceased to perform as promised.

The device’s intended permanence became central to the litigation. Plaintiffs alleged that when symptoms developed, stopping use was not an ordinary option; removing the implanted coils could require major surgery.

The women themselves changed the litigation. They compared symptoms, organized, spoke publicly about intimate injuries, and insisted that patterns dismissed in isolation be examined together. Fitzpatrick saw in that movement the force of self-advocacy—people trusting what their bodies were telling them and refusing to accept a convenient answer.

In 2020, Bayer announced agreements totaling approximately $1.6 billion to resolve most filed Essure claims in the United States. The legal record had grown from thousands of private medical histories into a national account of a device that each patient had first encountered alone.

Voice

Fitzpatrick’s cases are immense, but her stated source of energy is personal. She has said that meeting clients and becoming their voice keeps her moving when a case becomes difficult. That connection prevents scale from becoming abstraction.

In a lead case, the archive may contain a hundred years of corporate conduct, but the trial still turns on three men describing what reading has required of them. In a medical-device proceeding, tens of thousands of claims may share design and warning questions, but each file begins with one woman trying to understand pain no one predicted when the product was placed.

Fitzpatrick has tried pelvic-mesh bellwethers, led Essure proceedings, and accepted appointments in litigation involving Paragard IUDs, paraquat, and chemical hair relaxers. The products differ; the human problem remains recognizable. An injury once treated as private acquires a pattern. The pattern yields documents and science. Trial work returns the common proof to the person who lived it.

Her early gender-discrimination practice also remains present in that method. Much of her later docket involves women whose reports of pain or dysfunction were minimized until enough voices forced companies and courts to listen. Fitzpatrick brings those reports into discovery, expert analysis, and trial.

Products That Persist

Fitzpatrick’s product cases have involved lead pigment, contraceptive devices, and pelvic mesh—products whose long-term presence in homes or bodies made durability central to both their design and the injuries alleged.

Fitzpatrick’s litigation combines scientific evidence, company records, medical testimony, and product history to prove injuries that may emerge or persist long after sale or implantation.

Fitzpatrick has said that she enjoys approaching situations others consider impossible. In the California lead-paint litigation, that required tracing the promotion and continued presence of lead pigment across generations of ownership and repainting.

The litigation ultimately secured a public-abatement remedy directed at lead hazards still present in homes, connecting historical corporate evidence to present-day protection for affected families.